



## New-to-Market Medical Pharmacy Products Currently Under Clinical Review by Medica

Updated 3/24/2023

Brand name	Generic name	J code	National Drug Codes (NDCs)	Date of FDA approval
Aduhelm	aducanumab-avwa	J3590	64406-0101-01, 64406-0102-02	June 7, 2021
Adstiladrin	nadofaragene firadenovec-vncg	J9999	55566-1050-00	December 16, 2022
Altuviio	antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl	J3590	71104-978-01, 71104-979-01, 71104-980-01, 71104-981-01, 71104-982-01, 71104-983-01, 71104-984-01	February 22, 2023
Briumvi	ublituximab	J3590	73150-0150-06	December 28, 2022
Hemgenix	etranacogene dezaparvovec-drlb	J3590	00053-0099-01	November 22, 2022
Lamzede	velmanase alfa-tycv	J3590	10122-180-02, 10122-180-05, 10122-180-10	February 16, 2023
Legembi	lecanemab-irmb	J3590	62856-0215-01, 62856-0212-01	January 6, 2023
Lunsumio	mosunetuzumab-axgb	J9999	50242-0159-01, 50242-0142-01	December 22, 2022
Syfovre	pegcetacoplan	J3490	73606-0020-01	February 17, 2023
Tzield	teplizumab-mzww	J3590	73650-0316-01, 73650-0316-10, 73650-0316-14	November 17, 2022

*Note: Drugs recently removed from this list have been addressed under new [Medica drug management policies](#).*

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing are outside of Medica's control. Medica reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in [the New-to-Market Medical Pharmacy Products coverage policy](#).